EUCTR2006-005780-26-BE进行中（未招募）不适用
Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy plus Trastuzumab Regimens as Adjuvant Therapy in Patients with HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH. - Phase II Randomized Adjuvant Caelyx + Herceptin in Breast Cancer
Schering Plough Research Institute, a Division of Schering Corporation0 个研究点目标入组 180 人开始时间: 2007年10月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1) Subjects must demonstrate willingness to and be able to participate in the study and to adhere to dose and visit schedule;
- •2) Subjects must be of female gender and =18 years of age;
- •3) Subjects must have been diagnosed with operable, histological confirmed adenocarcinoma of the breast with no clinical or radiological evidence of metastatic disease but with otherwise high or intermediate risk tumor characteristics:
- •- node-positive: T1-3, N1-2, M0;
- •- node-negative AND at least one of the following features: tumor > 2 cm in diameter, OR tumor > 1cm and negative ER/PR, OR malignancy grade II/III, OR presence of peritumoral vascular invasion OR age < 35 Y
- •4) HER2-positive by FISH (with gene amplification) or 3+ using immunohistochemistry
- •5) Subjects must have had complete resection (R0) of the primary tumor and axillary lymph nodes (or must have negative sentinel node(s)).
- •6) Baseline LVEF by MUGA scan or echocardiogram (ECHO) = 55%.
- •7) ECOG-performance status of 0-1;
- •8) Adequate postoperative bone marrow function with neutrophils = 1.5 x 10exp9/l, platelets = 100 x 10exp9/l and hemoglobin = LLN;
- •9) Adequate renal function: calculated creatinine clearance = 50 ml/min.
- •10) Adequate postoperative liver function with with a total bilirubin < ULN, alkaline phosphatase < 2.5 times the ULN and AST < 1.5 times the ULN;
- •11) Subjects must be free of any clinically relevant disease that would, in the principal investigator’s and/or sponsor’s opinion, interfere with the conduct of the study or study evaluations;
- •12) Subjects of childbearing potential (including women who are less than 1 year postmenopausal and will be sexually active during the study) must agree to use a medically accepted method of contraception, while receiving protocol-specified medication and for 30 days after stopping the medication or be surgically sterilized prior to screening.
- •13) Subjects must be able to provide written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Clinical or radiological evidence of metastatic disease;
- •2) Prior radiotherapy, chemotherapy or biotherapy for the currently diagnosed breast cancer prior to randomization;
- •3) History of the following cancers:
- •?Ipsilateral breast cancer
- •?Invasive DCIS treated with any therapy other than excision
- •?Contralateral breast cancer
- •?History of non-breast malignancies witin the 5 years prior to study entry. Patients with the following cancers are eligible if diagnosed and treated within the previous 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin;
- •4) Clinically significant pericardial effusion;
- •5) Serious cardiac illness including, but not confined to
- •?History of documented congestive heart failure
- •?History of any form of cardiomyopathy or active treatment for any form of cardiomyopathy
- •?History of angina pectoris or documented transmural myocardial infarction, or active angina pectoris requiring medication
- •?Serious ventricular arrhythmias requiring medication or ICD therapy, uncontrolled supraventricular arrhythmias
- •?Clinically significant valvular disease
- •?Poorly controlled arterial hypertension (systolic BP > 180 mmHg, diastolic BP > 100 mmHg)
- •6) Sensory/motor neuropathy > grade 2 as defined by NCI-CTC;
- •7) Pregnancy or intending to become pregnant during the study;
- •8) Nursing (breastfeeding) or intending to be nursing during the study;
- •9) Any of the following clinical conditions:
- •?Chronic obstructive pulmonary disease, requiring chronic treatment
- •?Clinically significant active infections
- •?A history of a psychological illness of condition, preventing the subject to
- •understand the requirements of the study.
- •?Unstable regulation of diabetes mellitus
- •10) A situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study;
- •11) Is on staff, affiliated with,or a family member of the staff personnel directly involved with this study;
- •12) Usage of any investigational product within 30 days prior to enrollment;
- •13) Participation in any other interventional clinical study involving drug, device or biological. This would not prohibit the patient from participating in a QOL, questionnaire, blood collection, or observational study;
- •14) Allergy to or sensitivity to the study drug or its excipients.
研究者
相似试验
进行中（未招募）
不适用
Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy plus Trastuzumab Regimens as Adjuvant Therapy in Patients with HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH. - Phase II Randomized Adjuvant Caelyx + Herceptin in Breast CancerInvestigate patients with operable, node-positive or high-risk node-negative HER2-positive Breast Carcinoma.EUCTR2006-005780-26-PTIntegrated Therapeutics Group Inc.180
进行中（未招募）
不适用
Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy plus Trastuzumab Regimens as Adjuvant Therapy in Patients with HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH. - Phase II Randomized Adjuvant Caelyx + Herceptin in Breast CancerInvestigate patients with operable, node-positive or high-risk node-negative HER2-positive Breast Carcinoma.EUCTR2006-005780-26-NLSchering Plough180
进行中（未招募）
不适用
Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy plus Trastuzumab Regimens as Adjuvant Therapy in Patients with HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH. - Phase II Randomized Adjuvant Caelyx + Herceptin in Breast CancerEUCTR2006-005780-26-DESchering-Plough Research Institute, a Divison of Schering Corporation180
进行中（未招募）
不适用
Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy plus Trastuzumab Regimens as Adjuvant Therapy in Patients with HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH. - BACHInvestigate patients with operable, node-positive or high-risk node-negative HER2-positive Breast Carcinoma.MedDRA version: 6.1Level: PTClassification code 10006279EUCTR2006-005780-26-ITSCHERING-PLOUGH180
进行中（未招募）
不适用
A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer - BINGOadenocarcinoma of the biliary tract ( gallbladder, intra and/ or extrahepatic bile ducts, ampulla of Vater)EUCTR2007-001200-20-FRInstitut Gustave Roussy100